Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2025 Nov 3.
doi: 10.1002/acr.25690. Online ahead of print.

2025 American College of Rheumatology (ACR) Guideline for the Treatment of Systemic Lupus Erythematosus

Affiliations

2025 American College of Rheumatology (ACR) Guideline for the Treatment of Systemic Lupus Erythematosus

Lisa R Sammaritano et al. Arthritis Care Res (Hoboken). .

Abstract

Objective: To provide evidence-based and expert guidance for the treatment and management of non-renal systemic lupus erythematosus (SLE); treatment and management of lupus nephritis are addressed in a separate guideline.

Methods: Clinical questions for treatment and management of SLE were developed in the PICO format (population, intervention, comparator, and outcome). Systematic literature reviews were developed for each PICO question, and the Grading of Recommendations Assessment, Development, and Evaluation (GRADE) methodology was used to assess evidence quality and formulate recommendations. The Voting Panel achieved a consensus of ≥70% agreement on the direction (for or against) and strength (strong or conditional) of each recommendation.

Results: We present recommendations and ungraded, consensus-based good practice statements for the treatment and management of SLE that are applicable to pediatric and adult patients. Recommendations emphasize uniform treatment with hydroxychloroquine, limiting duration of glucocorticoid use, and early introduction of conventional and/or biologic immunosuppressive therapies to achieve and maintain control of SLE inflammation (remission or a low level of disease activity), reduce SLE-related morbidity and mortality, and minimize medication-related toxicities.

Conclusion: This guideline presents direction regarding treatment and management of SLE and provides a foundation for well-informed, shared clinician-patient decision-making. These recommendations should not be used to limit or deny access to therapies, as treatment decisions may vary due to the unique clinical situation and personal preferences of each person with SLE.

PubMed Disclaimer

References

REFERENCES

    1. Izmirly PM, Parton H, Wang L, et al. Prevalence of systemic lupus erythematosus in the United States: estimates from a meta‐analysis of the Centers for Disease Control and Prevention national lupus registries. Arthritis Rheumatol 2021;73:991–996.
    1. Dall'Era M, Cisternas MG, Snipes K, et al. The incidence and prevalence of systemic lupus erythematosus in San Francisco County, California: The California Lupus Surveillance Project. Arthritis Rheumatol 2017;69:1996–2005.
    1. Drenkard C, Lim SS. Update on lupus epidemiology: advancing health disparities research through the study of minority populations. Curr Opin Rheumatol 2019;31:689–696.
    1. Duarte‐García A, Hocaoglu M, Valenzuela‐Almada M, et al. Rising incidence and prevalence of systemic lupus erythematosus: a population‐based study over four decades. Ann Rheum Dis 2022;81:1260–1266.
    1. Ferucci ED, Johnston JM, Gaddy JR, et al. Prevalence and incidence of systemic lupus erythematosus in a population‐based registry of American Indian and Alaska Native people, 2007‐2009. Arthritis Rheumatol 2014;66:2494–2502.

LinkOut - more resources